Adial Pharmaceuticals (ADIL) Institutional Ownership $2.08 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.04 -0.04 (-1.73%) As of 05/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Adial Pharmaceuticals (NASDAQ:ADIL)CurrentInstitutional OwnershipPercentage16.41%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$15.92MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$46.10K Get ADIL Insider Trade Alerts Want to know when executives and insiders are buying or selling Adial Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ADIL Institutional Buying and Selling by Quarter Adial Pharmaceuticals Major Shareholders & Ownership History ExportReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/18/2026 Armistice Capital LLC2,554,442$562K0.0%N/A230.130% 2/12/2026 Jane Street Group LLC121,841$27K0.0%+887.3%10.967% 2/9/2026 Geode Capital Management LLC155,745$34K0.0%-5.1%14.018% 11/17/2025 Citadel Advisors LLC143,791$51K0.0%N/A0.599% 2/17/2025Citadel Advisors LLC54,508$55K0.0%+63.8%0.850% 2/13/2025Renaissance Technologies LLC47,613$48K0.0%N/A0.743% 2/12/2025Geode Capital Management LLC61,847$62K0.0%+36.0%0.965% 8/9/2024Renaissance Technologies LLC34,346$39K0.0%-32.8%0.811% 5/20/2024Virtu Financial LLC20,469$27K0.0%N/A0.484% 2/13/2024Armistice Capital LLC159,000$296K0.0%N/A9.578% 11/9/2023Manchester Capital Management LLC48,097$134K0.0%-96.0%3.942% 5/9/2023Manchester Capital Management LLC1,202,452$421K0.1%N/A4.216% 11/7/2022Virtu Financial LLC77,694$27K0.0%+142.7%0.301% 8/2/2022Thompson Davis & CO. Inc.21,000$28K0.0%N/A0.088% 7/22/2022Truist Financial Corp33,862$45K0.0%N/A0.142% 7/13/2022Private Advisor Group LLC21,400$29K0.0%-37.3%0.090% ADIL Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ADIL shares? During the previous two years, the following institutional investors and hedge funds held shares of Adial Pharmaceuticals shares: Armistice Capital LLC ($562K), Citadel Advisors LLC ($51K), Renaissance Technologies LLC ($48K), and Geode Capital Management LLC ($34K), Jane Street Group LLC ($27K).Learn more on Adial Pharmaceuticals' institutional investors. What percentage of Adial Pharmaceuticals' stock is owned by institutional investors? 16.41% of Adial Pharmaceuticals' stock is owned by institutional investors. Learn more on ADIL's institutional investor holdings. Which institutional investors have been buying Adial Pharmaceuticals' stock? The following institutional investors have purchased Adial Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($2.55M), Citadel Advisors LLC ($165.03K), Jane Street Group LLC ($109.50K), Renaissance Technologies LLC ($47.61K), and Geode Capital Management LLC ($16.38K). How much institutional buying is happening at Adial Pharmaceuticals? Institutional investors have bought a total of 2,807,733 shares in the last 24 months. This purchase volume represents approximately $15.92M in transactions. Which of Adial Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold Adial Pharmaceuticals stock in the last 24 months: Geode Capital Management LLC ($8.38K). How much institutional selling is happening at Adial Pharmaceuticals? Institutional investors have sold a total of 8,382 shares in the last 24 months. This volume of shares sold represents approximately $46.10K in transactions. Related Companies Quince Therapeutics Major Shareholders Exicure Major Shareholders Traws Pharma Major Shareholders Longeveron Major Shareholders Passage Bio Major Shareholders Natural Alternatives International Major Shareholders Applied Therapeutics Major Shareholders Cocrystal Pharma Major Shareholders GT Biopharma Major Shareholders Genenta Science Major Shareholders This page (NASDAQ:ADIL) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
